-+ 0.00%
-+ 0.00%
-+ 0.00%

LIXTE BIOTECHNOLOGY ANNOUNCES $16,566,027 REGISTERED DIRECT OFFERING PRICED AT THE MARKET UNDER NASDAQ RULES, STRENGTHENING BALANCE SHEET FOR NEXT PHASE OF STRATEGIC GROWTH

Reuters·06/03/2026 12:30:02

Please log in to view news